Computational profiling of verminoside at DNMT1, CDK2, and p15INK4b: a shared-pathway approach to AML, MDS, and Ewing Sarcoma
In Silico Research in Biomedicine · 2026 · 2 · 100716
DOI: 10.1016/j.insi.2026.100716 ↗Kurz gefasst
Fachartikel in der Zeitschrift In Silico Research in Biomedicine, 2026. Verfasst von Mohammed Dharvesh A und 4 weiteren Autor:innen. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Three cancers AML, myelodysplastic syndrome, and Ewing sarcoma arrive at the same point of failure by different paths: the loss of CDKN2B/p15INK4b, which releases CDK4/6 to phosphorylate Rb and pushes the cell into S phase through CDK2. Instead of treating these as three unrelated diseases needing three separate drugs, this study examined whether a single compound could be assessed against each point along that shared pathway. Verminoside, an iridoid glycoside isolated from Picrorhiza kurroa, was docked against DNMT1, CDK2, and p15INK4b using Glide XP, binding free energies were estimated by MM-GBSA, and the p15INK4b–verminoside complex, chosen because p15INK4b is the least characterised target and verminoside had the most favourable raw MM-GBSA value in that panel, was carried forward into a single 150-ns molecular dynamics simulation. For DNMT1, verminoside produced a docking score of −5.700 and an MM-GBSA value of −38.79 kcal/mol, with PHE C:389 as a key contact point set against azacitidine's −6.175 docking score and a near-zero MM-GBSA of +0.10 kcal/mol, though this comparison is constrained by azacitidine acting covalently, something docking calculations are not built to capture. Against CDK2, verminoside had a more favorable docking score than seliciclib (−9.448 vs −6.606) while retaining the hinge interaction at LEU 83, whereas seliciclib showed the more favorable MM-GBSA value (−7.59 vs −6.44 kcal/mol). The most striking result emerged at the ankyrin repeat interface of p15INK4b an undrugged site modeled through AlphaFold, where verminoside had the most favourable raw MM-GBSA value among the compounds tested (MM-GBSA: −49.07 kcal/mol; ligand efficiency ranked 4th of 8; IFD score: −310.41 kcal/mol, a composite Glide/Prime pose-ranking score rather than a binding free energy), making contact with Gly47, Arg49, Arg82, Glu71, and Asn73 in the docked pose. In the simulation, the ligand repositioned substantially (positional RMSD peak ∼42 Å; 15–90 ns) before reaching a plateau (15–16 Å; ∼90–150 ns), and the dominant simulated contacts differed from those in the docked pose. For this ankyrin surface, the comparison of verminoside with seliciclib and dalpiciclib is only a structural check, not a true measure of binding affinity. QikProp-based predictions further pointed to good aqueous solubility, minimal CNS exposure, low cardiotoxicity risk, and a profile better matched to non-oral delivery routes than to conventional tablets. Taken together, these results make a reasonable computational argument for verminoside as a candidate worth testing across three distinct cancers; whether it acts through one shared mechanism remains to be shown. The p15INK4b finding, since it is built on a predicted rather than crystallographically resolved structure, is put forward as a hypothesis to be tested experimentally, not as an established result.
Zitieren
APA
A, M. D., S, M. Z., N, I., N, A. H., & MH, M. A. (2026). Computational Profiling of Verminoside at DNMT1, CDK2, and p15INK4b: A Shared-Pathway Approach to AML, MDS, and Ewing Sarcoma. In Silico Research in Biomedicine, 100716. https://doi.org/10.1016/j.insi.2026.100716
Vancouver
A MD, S MZ, N I, N AH, MH MA. Computational Profiling of Verminoside at DNMT1, CDK2, and p15INK4b: A Shared-Pathway Approach to AML, MDS, and Ewing Sarcoma. In Silico Research in Biomedicine. 2026:100716. doi:10.1016/j.insi.2026.100716
BibTeX
@article{A2026,
author = {A, Mohammed Dharvesh and S, Mohammed Zaidh and N, Irfan and N, Abdul Hameed and MH, Mohamed Asrarullah},
title = {Computational Profiling of Verminoside at DNMT1, CDK2, and p15INK4b: A Shared-Pathway Approach to AML, MDS, and Ewing Sarcoma},
journal = {In Silico Research in Biomedicine},
year = {2026},
pages = {100716},
doi = {10.1016/j.insi.2026.100716}
}
EUVIMED